Phio reports 85% pathological response in highest dose cohort of PH-762 Phase 1b trial; no serious adverse events

Phio Pharmaceuticals Corp.

No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.
85% pathological response (6/7 patients) in final cohort; 4 of 6 responders had complete tumor clearance.
Overall response rate of 65% for squamous cell carcinomas (13/20 pathologic responders, including 9 complete).
FDA submission for next-step guidance targeted for Q2 2026; cGMP manufacturing expected in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.